Nutra Pharma Corp.
3473 High Ridge Road
Nutra Pharma Corporation is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. By bringing a solid business foundation to the Company's Biotech holdings, Nutra Pharma has the ability to accelerate business plans, streamline costs and bring products to the market or licensure in a time-effective manner.
The minority-owned subsidiary, ReceptoPharm, Inc, is developing technologies for the development of drugs for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis ("MS").
Nutra Pharma currently has three holdings:
The minority-owned holding, Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
Lastly, the wholly-owned subsidiary Portage BioMed is developing novel and proprietary drug delivery systems to be used with various drug therapies in the treatment of diseases. Their primary research is in creating innovative systems for the safer and more efficient distribution of existing chemotherapeutic agents in the treatment of cancer.
Rik J Deitsch, Chairman of the Board; President and Chief Executive Officer
Stanley J Cherelstein, Director; Principal Accounting Officer
Stewart Lonky, MD, Director; Science Chairman
Tanivir Khandaker, MD, Director; Partnerships and Acquisition Chairman
Michael Doherty, Chairman of the Board
Last Updated: 11-28-05
Nutra Pharma Corp.